Trung Huynh
Stock Analyst at UBS
(4.73)
# 140
Out of 5,131 analysts
57
Total ratings
69.23%
Success rate
24.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $105 → $130 | $121.41 | +7.08% | 4 | Jan 7, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $803.17 | -17.83% | 5 | Nov 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $895 → $1,080 | $1,040.00 | +3.85% | 10 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $148.75 | +49.92% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.14 | +2,092.98% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $369.19 | -14.14% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $22.97 | +65.43% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $27.58 | -9.35% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $60.74 | -11.10% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.80 | +150.00% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.26 | +79.06% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $243.45 | -28.12% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $231.50 | -26.57% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.32 | - | 1 | Mar 23, 2021 |
Merck & Co.
Jan 7, 2026
Maintains: Buy
Price Target: $105 → $130
Current: $121.41
Upside: +7.08%
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $803.17
Upside: -17.83%
Eli Lilly and Company
Nov 7, 2025
Maintains: Buy
Price Target: $895 → $1,080
Current: $1,040.00
Upside: +3.85%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $148.75
Upside: +49.92%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.14
Upside: +2,092.98%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $369.19
Upside: -14.14%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $22.97
Upside: +65.43%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $27.58
Upside: -9.35%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $60.74
Upside: -11.10%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.80
Upside: +150.00%
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $7.26
Upside: +79.06%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $243.45
Upside: -28.12%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $231.50
Upside: -26.57%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.32
Upside: -